AZD1390

Name: AZD1390
Brand: MedChemExpress
SKU: HY-109566
Rating: 5.0 (9 reviews)

Cat. No.: HY-109566 Purity: 99.22%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC₅₀ of 0.78 nM in cell.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 2089288-03-7

사이즈	재고	수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	해외재고보유	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	해외재고보유	Estimated Time of Arrival: December 31
Solid
1 mg	해외재고보유	Estimated Time of Arrival: December 31
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	견적 받기
500 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 9 publication(s) in Google Scholar

9 Publications Citing Use of MCE AZD1390

Cell Imaging/Staining

Others

In Vivo Efficacy Study

: AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]; Immunoblot analysis was performed on cell lysates extracted from ANV5-OE cells at different time points after treatment with IR (2 Gy), IR/ENPP1i (5 µM), IR/ATMi (AZD1390: 5 µM), or triple therapy to detect the protein expression levels of γHA2X, PARP1, cleaved PARP1 (c-PARP), ENPP1, RAD51, GAPDH, and Tubulin.

: AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]; The number of positive cells labeled with anti-γH2AX antibody was quantitatively assessed. Cells were incubated with ENPP1i (5 µM) and ATMi (AZD1390: 5 µM) for 24 h.

: AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]; After orthotopic transplantation of OE-ANV5 cells, mice were treated with FD (6.2 Gy × 4) alone, or in combination with ENPP1i (6 mg/kg, twice daily), ATMi (AZD1390: 5 mg/kg, once daily), or triple therapy (n = 8 mice per group), and changes in tumor volume were observed.

: AZD1390 purchased from MedChemExpress. Usage Cited in: EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]; HeLa cells expressing Flag‐tagged VDAC2 and V5‐tagged ANT2 were subjected to Co‐IP using anti‐Flag antibody and analyzed by western blot as indicated. ANT2, but not VDAC2, temporarily dissociated from DNA‐PKcs after treatment of 10 Gy IR. ATM knockdown and inhibition (AZD1390, 10 nM) disrupted the dissociation.

: AZD1390 purchased from MedChemExpress. Usage Cited in: EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]; Primary mouse embryonic fibroblasts (MEF) RPE-1 were analyzed for ADP-ATP exchange activity at different time points (up to 16 hours) in response to 100 μM H₂O₂. The ATM inhibitor (AZD1390, 10 nM) was also included in the parallel analysis.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ATM/ATR Isoform Specific Products:

View All Isoforms

ATM ATR TRRAP

Biological Activity
Protocol
순도&문서
References
고객리뷰

제품 설명

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC₅₀ of 0.78 nM in cell^[1].

IC₅₀ & Target^[1]

ATM

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
A549	IC₅₀	43 μM Compound: AZD1390	Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
COLO 205	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
HCT-116	IC₅₀	10.5 μM Compound: AZD1390	Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
HCT-116	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
HT-29	IC₅₀	> 10 μM Compound: AZD1390	Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35183872]
HT-29	IC₅₀	> 10 μM Compound: AZD1390	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37130473]
HT-29	IC₅₀	> 30 μM Compound: AZD1390	Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay	[PMID: 36462444]
K562	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
LoVo	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
NCI-H358	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
RKO	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW-620	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW13	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW480	IC₅₀	> 20 μM Compound: AZD1390	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]

In Vivo

Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

분자량

477.57

화학식

C₂₇H₃₂FN₅O₂

CAS No.

2089288-03-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2

선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

용액&용해도

In Vitro:

DMSO : 5 mg/mL (10.47 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0939 mL	10.4697 mL	20.9393 mL
5 mM	0.4188 mL	2.0939 mL	4.1879 mL
10 mM	0.2094 mL	1.0470 mL	2.0939 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (10.47 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (10.47 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

순도&문서

Purity: 99.22%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (247 KB) HNMR (201 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Durant ST, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018 Jun 20;4(6):eaat1719. [Content Brief]

[2]. J. Kahn, et al. Next-Generation ATM Kinase Inhibitors Under Development Radiosensitize Glioblastoma With Conformal Radiation in a Mouse Orthotopic Model. IJROBP. 2017. 99, 600-601.

Animal Administration
^[2]

Mouse GL261 glioma (p53 mutant) cells are implanted intra-cranially into immunocompetent, syngeneic C57/bl6 mice followed by bioluminescent imaging (BLI) prior to randomization. AZD1390 is administered by oral gavage prior to deliver multiple fractions of 2-3 Gy of radiation on 2 to 4 consecutive days. Radiation is administered via small animal radiation research platform (SARRP) irradiation to the site of the tumor with a 5×5 mm lateral ﬁeld^[2].

MCE 는 독립적으로 이러한 방법들의 정확성을 확인하지 않았습니다. 참고용으로만 봐주십시오.

References

[1]. Durant ST, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018 Jun 20;4(6):eaat1719. [Content Brief]

[2]. J. Kahn, et al. Next-Generation ATM Kinase Inhibitors Under Development Radiosensitize Glioblastoma With Conformal Radiation in a Mouse Orthotopic Model. IJROBP. 2017. 99, 600-601.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0939 mL	10.4697 mL	20.9393 mL	52.3483 mL
	5 mM	0.4188 mL	2.0939 mL	4.1879 mL	10.4697 mL
	10 mM	0.2094 mL	1.0470 mL	2.0939 mL	5.2348 mL

AZD1390 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AZD13902089288-03-7AZD 1390AZD-1390ATM/ATRAtaxia telangiectasia mutatedATM and RAD3 relatedInhibitorinhibitorinhibit

최근 본 상품:

상품명

Requested Quantity *

고객명 *

호칭

메일주소 *

전화번호 *

Department

회사명 *

City

도

Country or Region *

비고

상품명

Lot #

고객명 *

메일주소 *

전화번호

Department *

회사명 *

Country or Region *

비고

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

AZD1390

고객리뷰

AZD1390 Related Antibodies

9 Publications Citing Use of MCE AZD1390

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ATM/ATR Isoform Specific Products:

Biological Activity

Protocol

순도&문서

References

고객리뷰

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

AZD1390 Related Classifications

Keywords:

최근 본 상품:

고객리뷰

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report